A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

por Dittrich, Christian, Fridrik, Michael A., Koenigsberg, Robert, Lee, Chooi, Goeldner, Rainer-Georg, Hilbert, James, Greil, Richard
Publicado 2014

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

por Martin, Nicolas, Isambert, Nicolas, Gomez-Roca, Carlos, Goeldner, Rainer-Georg, Zanetta, Sylvie, Sadrolhefazi, Behbood, de Mont-Serrat, Hélène, Campone, Mario, Delord, Jean-Pierre
Publicado 2018

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

por Schnell, David, Buschke, Susanne, Fuchs, Holger, Gansser, Dietmar, Goeldner, Rainer-Georg, Uttenreuther-Fischer, Martina, Stopfer, Peter, Wind, Sven, Petersen-Sylla, Marc, Halabi, Atef, Koenen, Rüdiger
Publicado 2014

The natural history of progressive fibrosing interstitial lung diseases

por Brown, Kevin K., Martinez, Fernando J., Walsh, Simon L.F., Thannickal, Victor J., Prasse, Antje, Schlenker-Herceg, Rozsa, Goeldner, Rainer-Georg, Clerisme-Beaty, Emmanuelle, Tetzlaff, Kay, Cottin, Vincent, Wells, Athol U.
Publicado 2020

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease

por Maher, Toby M., Brown, Kevin K., Kreuter, Michael, Devaraj, Anand, Walsh, Simon L.F., Lancaster, Lisa H., Belloli, Elizabeth A., Padilla, Maria, Behr, Juergen, Goeldner, Rainer-Georg, Tetzlaff, Kay, Schlenker-Herceg, Rozsa, Flaherty, Kevin R.
Publicado 2022

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

por Flaherty, Kevin R., Wells, Athol U., Cottin, Vincent, Devaraj, Anand, Inoue, Yoshikazu, Richeldi, Luca, Walsh, Simon L.F., Kolb, Martin, Koschel, Dirk, Moua, Teng, Stowasser, Susanne, Goeldner, Rainer-Georg, Schlenker-Herceg, Rozsa, Brown, Kevin K.
Publicado 2022

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

por Brown, Kevin K., Inoue, Yoshikazu, Flaherty, Kevin R., Martinez, Fernando J., Cottin, Vincent, Bonella, Francesco, Cerri, Stefania, Danoff, Sonye K., Jouneau, Stephane, Goeldner, Rainer‐Georg, Schmidt, Martin, Stowasser, Susanne, Schlenker‐Herceg, Rozsa, Wells, Athol U.
Publicado 2022

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

por de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii
Publicado 2020